Quantcast
Last updated on April 18, 2014 at 15:19 EDT

Quest PharmaTech Initiates Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial in United States

June 14, 2012

TSX Venture: QPT

EDMONTON, June 14, 2012 /PRNewswire/ – Quest PharmaTech Inc. (TSX-V: QPT)
(“Quest” or the “Company”), a pharmaceutical company developing and
commercializing products for the treatment of cancer, announces that it
has received clearance from the United States Food and Drug
Administration to initiate U.S. sites for an ongoing international
Phase II clinical trial for oregovomab in advanced ovarian cancer
patients. The objective of this study is to evaluate whether optimally
dosed oregovomab in conjunction with front-line chemotherapy will
generate the same or an improved immune and clinical response, as seen
in a previous Phase II clinical trial in a similar ovarian cancer
patient population.

The U.S. centers include Michiana Hematology and Oncology at South Bend,
Indiana with Dr. Michael Method as the lead investigator; University of Connecticut Health Center at Farmington, Connecticut with
Dr. Molly R. Brewer as the lead investigator, and the Stanford Cancer
Institute at Stanford, California with Dr. Jonathan S. Berek as the
lead investigator.

Two of the three participating U.S. centers have received all necessary
regulatory approvals and are now actively recruiting patients. The
third center is awaiting IRB approval. Additional information on the
Company’s clinical trial can be found listed in www.ClinicalTrials.gov.

“A systemic study of combinatorial immunization strategies such as the
current trial with evidence based preliminary observations has the
potential of revolutionizing cancer therapy and may lead to important
commercial applications” said Dr. Christopher Nicodemus, MD, FACP,
Senior Advisor and Chairman of the Company’s Clinical Advisory Board.

“We are pleased with the interest from the U.S. centers to participate
in this important clinical trial. The additional centers will not only
speed up patient enrollment for the study, but will raise the profile
and awareness of Quest’s lead immunotherapy product in the ovarian
cancer community in North America”, said Dr. Madi R. Madiyalakan, PhD,
Chief Executive Officer for Quest.

About oregovomab

Quest PharmaTech is developing oregovomab, a high affinity monoclonal
antibody for the treatment of advanced ovarian cancer. Oregovomab
targets the circulating tumour associated antigen CA125. The unique
mechanism of action of this treatment involves infusion of oregovomab
at immune stimulatory doses (2mg) that specifically bind circulating
and local CA125. The antibody-antigen complex is taken up by dendritic
cells that, after processing, present the antigen fragments to T-cells
via the MHC system. The robust CD4 and CD8 T-cell response that follows
has been shown to be associated with a survival advantage, especially
when administered in combination with chemotherapy.

About Quest PharmaTech Inc.

Quest is a publicly traded, Alberta-based biotechnology company
committed to the development and commercialization of oncology product
candidates. It is developing a series of products for the treatment of
cancer based on its pipeline of SonoLight compounds; and monoclonal
antibodies which target certain tumour antigens that are presented in a
variety of cancers. The Company has active collaborations with major
comprehensive cancer care centers, and international experts, to
further the growing understanding of how to use antibodies to make a
patient’s own tumour markers become the patient’s own vaccine.

Quest believes that combinatorial immunotherapy, which exploits the
immune modulating effects of selected cytotoxic agents normally used in
standard chemotherapy regimens along with specific immune stimulants
will lead to important commercial applications of the Company’s
proprietary platform. Quest is currently conducting two carefully
planned, risk mitigating confirmatory clinical trials, not only to
validate the superiority of the combinatorial approach, but also to
design a definitive product registration study. The Company’s MUC1
antibody program has the potential to permit tumour specific
immunization to a broad range of additional cancers, including colon,
non small cell lung, breast and pancreas.

Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.

SOURCE Quest PharmaTech Inc.


Source: PR Newswire